Humanized mice supplemented with estradiol to support breast cancer tumor growth experienced severe anemia that was further worsened with concomitant treatment with anti-PD-1 (pembrolizumab) treatment, leading to decreased survival and early loss of mice. This evidence concerns the gene PDCD1 and neoplasm.